JP6697808B2 - 感覚有毛細胞の死を防ぐまたは処置するための化合物と方法 - Google Patents

感覚有毛細胞の死を防ぐまたは処置するための化合物と方法 Download PDF

Info

Publication number
JP6697808B2
JP6697808B2 JP2017538575A JP2017538575A JP6697808B2 JP 6697808 B2 JP6697808 B2 JP 6697808B2 JP 2017538575 A JP2017538575 A JP 2017538575A JP 2017538575 A JP2017538575 A JP 2017538575A JP 6697808 B2 JP6697808 B2 JP 6697808B2
Authority
JP
Japan
Prior art keywords
formula
alkyl
another embodiment
pharmaceutically acceptable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017538575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504411A5 (enExample
JP2018504411A (ja
Inventor
サイモン,ジュリアン
ジョンソン,グラハム
ダブリュ. ラベル,エドウィン
ダブリュ. ラベル,エドウィン
ダブリュ. ライブル,デイビッド
ダブリュ. ライブル,デイビッド
ディー. ゴンザレス,マリオ
ディー. ゴンザレス,マリオ
シー. メルツァー,ピーター
シー. メルツァー,ピーター
ミャオ,ウェイシ
Original Assignee
ユニヴァーシティ オブ ワシントン
ユニヴァーシティ オブ ワシントン
フレッド ハッチンソン キャンサー リサーチ センター
フレッド ハッチンソン キャンサー リサーチ センター
オリキュラ セラピューティクス エルエルシー
オリキュラ セラピューティクス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オブ ワシントン, ユニヴァーシティ オブ ワシントン, フレッド ハッチンソン キャンサー リサーチ センター, フレッド ハッチンソン キャンサー リサーチ センター, オリキュラ セラピューティクス エルエルシー, オリキュラ セラピューティクス エルエルシー filed Critical ユニヴァーシティ オブ ワシントン
Publication of JP2018504411A publication Critical patent/JP2018504411A/ja
Publication of JP2018504411A5 publication Critical patent/JP2018504411A5/ja
Application granted granted Critical
Publication of JP6697808B2 publication Critical patent/JP6697808B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017538575A 2015-02-06 2016-02-05 感覚有毛細胞の死を防ぐまたは処置するための化合物と方法 Active JP6697808B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113245P 2015-02-06 2015-02-06
US62/113,245 2015-02-06
PCT/US2016/016880 WO2016127123A2 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death

Publications (3)

Publication Number Publication Date
JP2018504411A JP2018504411A (ja) 2018-02-15
JP2018504411A5 JP2018504411A5 (enExample) 2019-03-14
JP6697808B2 true JP6697808B2 (ja) 2020-05-27

Family

ID=56564889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538575A Active JP6697808B2 (ja) 2015-02-06 2016-02-05 感覚有毛細胞の死を防ぐまたは処置するための化合物と方法

Country Status (10)

Country Link
US (2) US9493482B2 (enExample)
EP (1) EP3253766B1 (enExample)
JP (1) JP6697808B2 (enExample)
KR (1) KR102557184B1 (enExample)
CN (1) CN107438613B (enExample)
AU (1) AU2016215023B2 (enExample)
CA (1) CA2974395C (enExample)
DK (1) DK3253766T3 (enExample)
ES (1) ES2760373T3 (enExample)
WO (1) WO2016127123A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127123A2 (en) 2015-02-06 2016-08-11 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
DK3675865T3 (da) 2017-09-01 2025-05-26 Univ Washington Krystallinske former af forbindelser til forebyggelse eller behandling af sensorisk hårcelledød
WO2020033322A1 (en) * 2018-08-06 2020-02-13 Fred Hutchinson Cancer Research Center Hearing loss-protective compounds and methods thereof
US20240350492A1 (en) 2020-07-10 2024-10-24 Ting Therapeutics Llc Methods for the Prevention and Treatment of Hearing Loss
KR102848315B1 (ko) * 2022-10-27 2025-08-20 고려대학교 산학협력단 암모늄 락테이트를 유효성분으로 포함하는 난청 예방 또는 치료용 약학 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES457780A1 (es) 1977-04-14 1978-08-16 Made Labor Sa Un procedimiento para la obtencion de 7,10-dimetil-5,9-imi- no-4,5,8,9 - tetrahidrocicloocta (b) tiofenos.
ES462993A1 (es) 1977-10-07 1978-06-01 Made Labor Sa Un procedimiento para la obtencion simultanea de 6,7,10-tri-metil-5,9-imino-4,5,8,9-tetrahidrocicloocta(b)furano y de alfa-2,4,5-trimetilfuro(2,3-f)morfano.
US4174396A (en) 1978-04-03 1979-11-13 Laboratories Made, S.A. 7,10-Dimethyl-5,9-imino-4,5,8,9-tetrahydro-cyclooct[b]thiophenes and a process for obtaining it
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
JPH0778017B2 (ja) 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
ES2149781T3 (es) 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
WO2003002569A1 (en) 2001-06-29 2003-01-09 Novo Nordisk A/S Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48
CA2572750A1 (en) 2003-09-10 2005-03-17 Anil Koul Heterobicyclic compounds as pharmaceutically active agents
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
US20060188445A1 (en) 2005-02-22 2006-08-24 Fred Hutchinson Cancer Research Center Assay for compounds that protect against sensory hair cell death and compounds identified by same
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20110158911A1 (en) 2009-07-01 2011-06-30 Trustees Of Dartmouth College Methods for Screening for Antibiotic Compounds
DK2900674T3 (en) * 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
WO2016127123A2 (en) 2015-02-06 2016-08-11 University Of Washington Compounds and methods for preventing or treating sensory hair cell death

Also Published As

Publication number Publication date
KR20180003530A (ko) 2018-01-09
WO2016127123A3 (en) 2016-10-27
AU2016215023B2 (en) 2019-12-19
US20160229869A1 (en) 2016-08-11
CN107438613B (zh) 2020-08-25
US10399994B2 (en) 2019-09-03
HK1246791A1 (en) 2018-09-14
DK3253766T3 (da) 2019-12-09
US20180022756A1 (en) 2018-01-25
KR102557184B1 (ko) 2023-07-18
EP3253766A2 (en) 2017-12-13
CA2974395A1 (en) 2016-08-11
CN107438613A (zh) 2017-12-05
ES2760373T3 (es) 2020-05-13
CA2974395C (en) 2023-08-22
EP3253766A4 (en) 2018-07-25
US9493482B2 (en) 2016-11-15
EP3253766B1 (en) 2019-09-04
JP2018504411A (ja) 2018-02-15
AU2016215023A1 (en) 2017-09-07
WO2016127123A2 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
JP6697808B2 (ja) 感覚有毛細胞の死を防ぐまたは処置するための化合物と方法
US9902738B2 (en) Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
CN111662281B (zh) 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途
CN103906749A (zh) 原小檗碱类生物碱衍生物及其抗溃疡性结肠炎的用途
JP2022078094A (ja) Olig2活性の阻害
CN109734614B (zh) 3-羟基查尔酮曼尼希碱类化合物、其制备方法和用途
WO2020024977A1 (zh) 用于治疗神经系统疾病的化合物及其应用
EP1911451A1 (en) Protein-kinase CK2 inhibitors and their therapeutic applications
JP2012532150A (ja) 13a−(S)脱酸チロホリニンの塩、医薬組成物と用途
CN106798743A (zh) (n‑异丙基哌嗪基)‑2‑羟基苯甲酰胺化合物在制备治疗神经退行性疾病药物中的用途
US20250376455A1 (en) 2-diarylmethyl-4-aminotetrahydropyran derivatives and related compounds as anticancer, antiinflammatory, antifibrotic and neuroprotective agents
HK1246791B (en) Compounds and methods for preventing or treating sensory hair cell death
CN111285843A (zh) 新型5-羟色胺和去甲肾上腺素双重再摄取抑制剂及其医药用途
CN109678736B (zh) 查尔酮曼尼希碱类化合物、其制备方法和用途
CN117003771A (zh) 一种抗流感病毒衍生物及其用途
CN105330708A (zh) 延胡索乙素衍生物及其制备方法、用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200424

R150 Certificate of patent or registration of utility model

Ref document number: 6697808

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250